Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03383731
Other study ID # Shanghai1stWFH
Secondary ID
Status Recruiting
Phase N/A
First received December 6, 2017
Last updated December 19, 2017
Start date April 7, 2017
Est. completion date April 6, 2020

Study information

Verified date December 2017
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact Fenghua Wang
Phone +8618917504061
Email shretina@sjtu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the surgical outcomes of inverted internal limiting membrane insertion combined with air tamponade in the treatment of macular hole retinal detachment (MHRD) in high myopia, and also to compare the treatment efficacy and safety between different surgical approaches of MHRD


Description:

This study uses a new surgical method (vitrectomy combined with inverted internal limiting membrane insertion and intraocular sterilized air tamponade) to assess its effectiveness and safety on the prognosis of macular hole retinal detachment secondary to high myopia, and also compares this new type of surgery with the current commonly used surgery (vitrectomy combined with internal limiting membrane peeling + silicone oil infusion).


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date April 6, 2020
Est. primary completion date April 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Prior written informed consent should be obtained before any assessment is carried out;

2. Participants are more than 18 years of age, and less than 75 years of age, male or female Chinese patients;

3. Visual impairment is caused by macular hole associated with retinal detachment secondary to high myopia;

4. Axial length = 26mm, or the refractive error = -6.0D

Exclusion Criteria:

1. Failure to comply with research or follow-up procedures;

2. Diabetes with uncontrolled blood glucose (defined as fasting plasma glucose more than 7.0mmol/L or blood glucose more than 11.1mmol/ L 2 hours postprandial), and / or with diabetic retinopathy;

3. Poor control of blood pressure in hypertensive patients (defined as blood pressure >150/95mmHg, including antihypertensive medication);

4. With surgical contraindication due to other local or systemic conditions at screening or baseline;

5. With any active ocular or periocular infection or inflammation (e.g., blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) at screening or baseline;

6. With uncontrolled glaucoma at screening or baseline (IOP = 30mmHg when receiving medical treatment or as judged by the researchers);

7. With the presence of iris neovascularization or neovascular glaucoma at screening or baseline;

8. With ocular diseases which may interfere the study results at screening or baseline , including severe vitreous hemorrhage, peripheral retinal hole, proliferative diabetic retinopathy, proliferative vitreoretinopathy ( = Level C ), choroidal detachment;

9. With other causes which may result in macular hole associated-retinal detachment at screening or baseline,except high myopia;

10. Previously underwent scleral buckling surgery;

11. With current or planned medication known to have toxic effects on the lens, retina or optic nerve, including hydroxychloroquine, chloroquine, hydroxychloroquine, tamoxifen, phenothiazine and ethambutol;

12. With laboratory abnormalities, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), exceeded the normal limit by more than 2 times, and serum creatinine or blood urea nitrogen exceeded 1.2 times the normal limit;

13. With abnormal coagulation function (defined as more than normal prothrombin time for 3 seconds or more, more than 1.5 of the international standard ratio (INR), activated partial thromboplastin time of 10 seconds or longer than the upper limit of normal time); 14) Patients who participated in any clinical study of medication within 3 months prior to screening (excluding vitamins and minerals)

Exit criteria:

1. Due to adverse events, especially severe adverse events, the researchers consider withdrawal of patients based on concerns of safety and ethics;

2. Drop out;

3. The patients voluntarily withdraw the informed consent;

4. Serious violation of the study protocol due to the subjects or investigators' reasons;

5. Other reasons that the researchers believe for quitting the study

Study Design


Intervention

Procedure:
Group 1
the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
Group 2
the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange

Locations

Country Name City State
China Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

References & Publications (14)

Feman SS, Hepler RS, Straatsma BR. Rhegmatogenous retinal detachment due to macular hole. Management with cryotherapy and a Y-shaped sling. Arch Ophthalmol. 1974 May;91(5):371-2. — View Citation

Hasegawa Y, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Noda Y, Ishibashi T. Equivalent tamponade by room air as compared with SF(6) after macular hole surgery. Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1455-9. doi: 10.1007/s00417-009-1120-8. Epub 2009 Jun 21. — View Citation

He F, Dong F, Yu W, Dai R. Recovery of photoreceptor layer on spectral-domain optical coherence tomography after vitreous surgery combined with air tamponade in chronic idiopathic macular hole. Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):44-8. doi: 10.3928/23258160-20150101-07. — View Citation

Hong MC, Wu TT, Sheu SJ. Primary gas tamponade in the management of macular hole with retinal detachment in highly myopic eyes. J Chin Med Assoc. 2011 Mar;74(3):121-4. doi: 10.1016/j.jcma.2011.01.026. Epub 2011 Feb 25. — View Citation

Kuriyama S, Hayashi H, Jingami Y, Kuramoto N, Akita J, Matsumoto M. Efficacy of inverted internal limiting membrane flap technique for the treatment of macular hole in high myopia. Am J Ophthalmol. 2013 Jul;156(1):125-131.e1. doi: 10.1016/j.ajo.2013.02.014. Epub 2013 Apr 24. — View Citation

Li X, Wang W, Tang S, Zhao J. Gas injection versus vitrectomy with gas for treating retinal detachment owing to macular hole in high myopes. Ophthalmology. 2009 Jun;116(6):1182-87.e1. doi: 10.1016/j.ophtha.2009.01.003. Epub 2009 Apr 17. — View Citation

Lim LS, Tsai A, Wong D, Wong E, Yeo I, Loh BK, Ang CL, Ong SG, Lee SY. Prognostic factor analysis of vitrectomy for retinal detachment associated with myopic macular holes. Ophthalmology. 2014 Jan;121(1):305-10. doi: 10.1016/j.ophtha.2013.08.033. Epub 2013 Oct 16. — View Citation

Mateo-Montoya A, de Smet MD. Air as tamponade for retinal detachments. Eur J Ophthalmol. 2014 Mar-Apr;24(2):242-6. doi: 10.5301/ejo.5000373. Epub 2013 Sep 23. — View Citation

Mete M, Parolini B, Maggio E, Pertile G. 1000 cSt silicone oil vs heavy silicone oil as intraocular tamponade in retinal detachment associated to myopic macular hole. Graefes Arch Clin Exp Ophthalmol. 2011 Jun;249(6):821-6. doi: 10.1007/s00417-010-1557-9. Epub 2010 Nov 16. — View Citation

Michalewska Z, Michalewski J, Dulczewska-Cichecka K, Adelman RA, Nawrocki J. TEMPORAL INVERTED INTERNAL LIMITING MEMBRANE FLAP TECHNIQUE VERSUS CLASSIC INVERTED INTERNAL LIMITING MEMBRANE FLAP TECHNIQUE: A Comparative Study. Retina. 2015 Sep;35(9):1844-50. doi: 10.1097/IAE.0000000000000555. — View Citation

Miyake Y. A simplified method of treating retinal detachment with macular hole. Long-term follow-up. Arch Ophthalmol. 1986 Aug;104(8):1234-6. — View Citation

Shin MK, Park KH, Park SW, Byon IS, Lee JE. Perfluoro-n-octane-assisted single-layered inverted internal limiting membrane flap technique for macular hole surgery. Retina. 2014 Sep;34(9):1905-10. doi: 10.1097/IAE.0000000000000339. — View Citation

Soheilian M, Ghaseminejad AK, Yazdani S, Ahmadieh H, Azarmina M, Dehghan MH, Moradian S, Anisian A, Peyman GA. Surgical management of retinal detachment in highly myopic eyes with macular hole. Ophthalmic Surg Lasers Imaging. 2007 Jan-Feb;38(1):15-22. — View Citation

Uemoto R, Yamamoto S, Tsukahara I, Takeuchi S. Efficacy of internal limiting membrane removal for retinal detachments resulting from a myopic macular hole. Retina. 2004 Aug;24(4):560-6. — View Citation

* Note: There are 14 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other The number of people whose best corrected visual acuity (BCVA) result improves The number of people whose BCVA result improves by more than 1 row, 2 rows and 3 rows comparing to the baseline at a time 12 months after the operation
Other The number of people whose BCVA result decreases The number of people whose BCVA result decreases by 3 rows comparing to the baseline at a time 12 months after the operation
Other The difference of multifocal electroretinogram (ERG) results The difference of multifocal ERG results between each group from 1 week to the 6th month after surgery 6 months after the operation
Other The difference of multifocal ERG results The difference of multifocal ERG results between each group from 1 week to the 12th month after surgery 12 months after the operation
Other The change of microperimetry analysis results The change of microperimetry analysis results from 1 week to the 6th month after surgery relative to baseline, and the difference between each group 6 months after the operation
Other The change of microperimetry analysis results The change of microperimetry analysis results from 1 week to the 12th month after surgery relative to baseline, and the difference between each group 12 months after the operation
Other The change of the extent of foveal ellipsoid zone damage The change of the extent of foveal ellipsoid zone damage from baseline to the 6th month after the surgery relative to baseline, and the difference between each group 6 months after the operation
Other The change of the external limiting membrane integrity of fovea The change of the external limiting membrane integrity of fovea from baseline to the 6th month after the surgery relative to baseline, and the difference between each group 6 months after the operation
Other The change of the extent of foveal ellipsoid zone damage The change of the extent of foveal ellipsoid zone damage from baseline to the 12th month after the surgery relative to baseline, and the difference between each group 12 months after the operation
Other The change of the external limiting membrane integrity of fovea The change of the external limiting membrane integrity of fovea from baseline to the 12th month after the surgery relative to baseline, and the difference between each group 12 months after the operation
Other The number of retreatment and retreatment modalities ? Describe the number of retreatment and retreatment modalities for patients with different surgical procedures over a period of 12 months within 12 months after the operation
Primary Macular hole closure rate Fundus examination combined with optical coherence tomography (OCT) are performed 3 months after surgery. 3 months after operation
Secondary Best corrected visual acuity Best corrected visual acuity are performed 6 months after the surgery. 6 months after the operation
Secondary Best corrected visual acuity Best corrected visual acuity are performed 12 months after the surgery. 12 months after the operation
Secondary Reattachment rate of retinal detachment Use fundus examination combined with B-scan ultrasound, optical coherence tomography (OCT) to observe the reattachment rate of retinal detachment within 12 months after the surgery.(The reattachment rate assessment is performed 12 months after the first surgery among the patients with air tamponade. The reattachment rate assessment is performed 12 months after the first surgery among the patients with silicone oil tamponade, and the silicone oil removal is performed 6 months after the previous surgery.) 6 months after the operation
Secondary Reattachment rate of retinal detachment Use fundus examination combined with B-scan ultrasound, optical coherence tomography (OCT) to observe the reattachment rate of retinal detachment within 12 months after the surgery.(The reattachment rate assessment is performed 12 months after the first surgery among the patients with air tamponade. The reattachment rate assessment is performed 12 months after the first surgery among the patients with silicone oil tamponade, and the silicone oil removal is performed 6 months after the previous surgery.) 12 months after the operation
Secondary Postoperative complication rate of ocular adverse events Evaluate the ocular adverse events within 12 months after operation. Within 12 months after operation
Secondary Postoperative complication rate of the non ocular adverse events Evaluate the non ocular adverse events within 12 months after operation. Within 12 months after operation
Secondary Postoperative complication rate of severe adverse events Evaluate the severe adverse events within 12 months after operation. Within 12 months after operation
See also
  Status Clinical Trial Phase
Completed NCT03332758 - Inflammasomes in Cell Death in FTMH, ERM, and RRD
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT04535622 - Efficacy of Exercise Program for Facedown Posture-related Pain After Retinal Surgery N/A
Recruiting NCT05863312 - REtinal Detachment Outcomes Study N/A
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT03046719 - Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal N/A
Recruiting NCT01261533 - Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Phase 1
Terminated NCT02068625 - Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Phase 4
Completed NCT00000140 - The Silicone Study Phase 3
Recruiting NCT05543018 - Effect of Intraocular Tamponade on Visual Perception N/A
Not yet recruiting NCT04518696 - Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment N/A
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Enrolling by invitation NCT05566626 - Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera N/A
Not yet recruiting NCT03631108 - Feasibility Study and Preliminary Application Study on Iris OCTA
Recruiting NCT02201706 - Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye N/A
Completed NCT03218371 - Scleral Self-indentation Chandelier-assisted Peripheral Vitrectomy Under Air Rhegmatogenous Retinal Detachment. N/A
Completed NCT00000154 - Diabetic Retinopathy Vitrectomy Study (DRVS) Phase 3